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Abstract Human milk cholesterol esterase (bile salt-activated 
lipase) plays a role in the dietary uptake of triacylglyceride and 
cholesteryl ester. The activities toward these substrates are 
mediated through a unique bile salt-activated mechanism. 
Previously, it has been proposed that a necessary step in this 
process is prior protein dimerisation in the presence of primary 
bile salts. In this study, we addressed the role of protein 
dimerisation by investigating bile salt interactions on full length 
and truncated recombinant forms, as analysed by size exclusion 
chromatography and concanavalin A Sepharose binding experi-
ments. The present findings demonstrate that protein dimerisa-
tion is not an obligatory component of the bile salt-activated 
pathway. A new functional role for the glycosylated C-terminal 
domain in cholesterol esterase is also demonstrated in the 
prevention of non-specific hydrophobic interactions. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cholesterol esterase (bile salt-activated lipase) belongs to 
the cholinesterase family of proteins and hydrolyses a broad 
range of substrates including triacylglycerides and cholesteryl 
esters [1]. It is secreted by the exocrine pancreas and by a 
number of species in the milk where it ensures efficient lipid 
uptake in the newborn. As shown from cDNA cloning, the 
milk and pancreatic forms of cholesterol esterase are derived 
from the same gene [2]. Cholesterol esterase has also been 
identified in plasma [3] and evidence suggests it is involved 
in lipoprotein metabolism [4,5]. Recently, its role in the up-
take of dietary cholesteryl ester has been established by stud-
ies with gene knockout mice [6]. 
Cholesterol esterase possesses a unique bile salt activation 
mechanism in which the hydrolysis of emulsified long chain 
triacylglyceride and cholesteryl esters is dependent on primary 
bile salts [1]. This phenomenon has been explained in terms of 
a protein activation site that recognises specifically the 7a-
hydroxyl group of primary bile salts [7]. However, this group 
is not the sole structural component required for activation, as 
demonstrated with CHAPS. This bile salt analogue binds to 
cholesterol esterase without causing activation, presumably by 
preventing subsequent interfacial binding to a lipid emulsion 
[8]. Therefore, other steroidal side chains are also important 
for enzyme/substrate interactions [8]. 
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Based on early evidence, it has been proposed in terms of a 
two site model that bile salt activation proceeds through pro-
tein dimerisation [7,9]. Here, binding of primary bile salts at 
the activation site induces dimerisation of cholesterol esterase 
and subsequent activation [7]. In contrast, secondary bile 
salts, which do not activate and lack a 7ct-hydroxyl group, 
bind at a distinct lipid-binding promoting site without causing 
dimerisation [7]. Recently, a molecular interpretation for pro-
tein dimerisation has been advocated, based on a computer-
generated tertiary structure for the salmon isoform (carboxyl-
ester lipase) modeled on the related acetylcholinesterase terti-
ary structure [10]. 
Despite a two site interpretation of bile salt binding and 
evidence for bile salt-induced conformational changes [11], 
whether protein dimerisation is integral to the activation 
mechanism has not been conclusively established. In the 
present study, the role of protein dimerisation was addressed 
by investigating bile salt interactions on full length and trun-
cated recombinant forms of cholesterol esterase. The fully 
active truncated mutant lacked a novel glycosylated C-termi-
nal domain [12], comprising a proline-rich repetitive consen-
sus sequence [2]. By studying the effects of bile salts on these 
recombinant forms using size exclusion chromatography and 
concanavalin A Sepharose binding, the present findings dem-
onstrate that protein dimerisation is not required for bile salt 
activation. Furthermore, differences observed between the two 
recombinant forms implicate a new functional role for the 
glycosylated C-terminal domain in counteracting non-specific 
hydrophobic interactions. 
2. Materials and methods 
2.1. Cloning and expression 
cDNA sequences encoding full length (residues 1-722) and trun-
cated cholesterol esterase (residues 1-518) were cloned from a XgtlO 
cDNA library constructed from lactationally competent human breast 
tissue (Clontech), as described previously [12]. The truncated variant 
lacked the glycosylated C-terminal domain starting from position 536 
and a preceding polypeptide, Leu519-Gln535. Due to differential gly-
cosylation [13], both the truncated and full length recombinant forms 
are secreted from their respective stable cell lines as various protein 
bands, as analysed by SDS-PAGE. These are 58 kDa and 63 kDa for 
the truncated recombinant form and 115 kDa/117 kDa and 120 kDa 
for the full length recombinant form. 
2.2. Purification of recombinant cholesterol esterases 
Recombinant cholesterol esterases were purified as described previ-
ously [12] with one modification. Namely, after anion exchange (Q-
Sepharose, Pharmacia), active fractions were loaded onto a heparin 
Sepharose step (Hep-Pac cartridge, Pharmacia) in 10 mM sodium 
phosphate, pH 7.6, and the recombinant cholesterol esterases eluted 
with a NaCl gradient. No differences between the elution positions 
between the full length and truncated recombinant forms were ob-
served. The purified proteins were concentrated by ultracentrifugation 
(Amicon) and analysed by SDS-PAGE. 
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2.3. Concanavalin A binding 
Either full length or truncated recombinant forms were loaded onto 
concanavalin A Sepharose (Pharmacia) equilibrated with 10 mM so-
dium phosphate, pH 7.6, with various concentrations of NaCl or 
CHAPS as indicated in the figure legend. Of the recombinant forms, 
the 63 kDa (truncated) and 120 kDa (full length) species respectively 
were retained by the column, compatible with the presence of protein 
AMinked glycosylation. After complete elution of unbound material, 
these 7V-glycosylated species were eluted with 0.2 M methyl-a-D-glu-
copyranoside. For the binding experiments, eluted proteins were con-
centrated by ultracentrifugation (amicon) and analysed by SDS/ 
PAGE using 10% or 7.5% acrylamide gels for truncated and full 
length recombinant forms respectively. 
3. Results and discussion 
3.1. Bile salt interactions with human cholesterol esterase 
To investigate bile salt interactions, size exclusion chroma-
tography was performed on the truncated mutant in the pres-
ence of the primary bile salt sodium cholate (Fig. 1). Interest-
ingly, at a submicellar concentration of sodium cholate, 
sufficient to activate enzyme activity (2 mM), there was no 
change in the apparent molecular mass exhibited by the trun-
cated mutant at approximately 61 kDa (major peak). Nor was 
there any change when sodium cholate was substituted for 
identical concentrations of the secondary bile salt, sodium 
deoxytaurocholate, or the bile salt analogue CHAPS. The 
minor peak at approximately 80 kDa is attributable to traces 
of transferrin originally present in the cell culture media, as 
indicated by SDS-PAGE. Identical results were also obtained 
with the full length recombinant cholesterol esterase. Thus, 
submicellar concentrations of either these bile salts, or the 
bile salt analogue, CHAPS, had no effect on the apparent 
molecular mass at approximately 300 kDa (not shown). 
These results resolve conflicting ultracentrifugation evidence 
concerning the effect of submicellar primary bile salts on the 
molecular size of the enzyme [7,14]. Rather, as both primary 
and secondary bile salts cause cholesterol esterase to bind to 
emulsion particles [8], bile salt activation is likely mediated 
through conformational factors. This alternative mechanism 
is supported by circular dichroism spectropolarimetry on the 
rat isoform [11]. 
The interaction of cholesterol esterase with micellar bile salt 
has also received attention in the literature [9,10]. On the basis 
of chemical modification protection studies, it has been pro-
posed that a functional micellar binding site is formed from a 
premicellar bile salt binding site through dimerisation. As mi-
cellar bile salt could potentially interact differently than the 
dispersed bile salt form, this possibility was investigated. 
For the full length recombinant form, micellar concentra-
tions (10 mM) of either sodium cholate, sodium deoxytauro-
cholate, or the bile salt analogue CHAPS, shifted the apparent 
molecular mass from 300 kDa to approximately 510 kDa (not 
shown). However, the possibility that this molecular mass 
shift was due to protein dimerisation was discounted on the 
basis of identical experiments with the truncated mutant in 
which the apparent molecular mass increased from 61 kDa 
to approximately 70 kDa (Fig. 1). Reinjection of the 70 
kDa peak onto the column re-equilibrated without bile salt 
partially resolved both 70 kDa and 61 kDa peaks suggesting 
an interaction between the protein and the bile salt micelle 
(not shown). These results strongly suggest that cholesterol 
esterase does not dimerise in the presence of micellar bile 
salt. Instead, the observed molecular mass shift for the full 



















Fig. 1. Bile salt interactions with the truncated mutant. Truncated 
recombinant cholesterol esterase (60 irg protein) was resolved on a 
Superose-12 column (Pharmacia) equilibrated with 10 mM sodium 
phosphate, pH 7.6, +0.1 M NaCl. In the absence or presence of 
submicellar (2 mM) sodium cholate, the truncated mutant exhibited 
an apparent molecular mass at 61 kDa (major peak). Micellar so-
dium cholate (10 mM) shifted this peak position to an apparent 
molecular mass of 70 kDa, as indicated by the arrow (trace not 
shown). 
length enzyme is likely due to the non-globular behaviour of 
the solvated protein [15] conferred by the C-terminal glycosyl-
ated domain. 
Additional support that protein dimerisation does not occur 
was provided by concanavalin A binding studies of differen-
tially glycosylated full length forms (Fig. 2, right panel). As 
indicated by SDS-PAGE, the full length recombinant choles-
terol esterase is secreted from the mammalian cell culture 
system as three protein forms: a 120 kDa species which is 
immobilised by concanavalin A sepharose; and two 115/117 
kDa concanavalin A non-binding forms. If dimerisation oc-
curs in the presence of primary bile salts, it would be possible 
to detect an association between these various glycosylated 
forms. However, no association was observed under condi-
tions in which bile salt activation occurs (far right). Thus, a 
functional micellar binding site is not formed through dimer-
isation as originally proposed [9]. 
3.2. Role of the C-terminal glycosylated domain in the 
prevention of aggregation 
An enigma particular to cholesterol esterase is how protein 
aggregation in the inactive state is prevented. For many other 
characterised lipases displacement of a 'lid' overhanging the 
active site can augment exposure of hydrophobic surfaces 
surrounding the active site cavity [16,17]. In the closed 
form, aggregation is largely prevented through shielding of 
hydrophobic patches from the bulk solvent [18]. For choles-
terol esterase, however, structural predictions [10] and limited 
proteolysis [12] suggest the presence of permanently exposed 
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Fig. 2. Concanavalin A Sepharose binding of full length (F) and truncated (T) recombinant forms. Left panel: Association of 58 kDa and 63 
kDa truncated forms (5 ug total protein in each lane). From left: 58 kDa and 63 kDa truncated forms prior to loading onto concavalin A; un-
bound 58 kDa form; elution of the 63 kDa form with 0.2 M methyl-a-D-glucopyranoside (indicated by + signs) in the presence of 50 mM 
NaCl, 0.5 M NaCl, and 0.5 M NaCl+2 mM CHAPS. Right panel: Separation of full length glycosylated recombinant forms. From left: glyco-
sylated forms prior to loading onto concanavalin A; unbound 115/117 kDa forms; elution of 120 kDa form with 0.2 M methyl-a-D-glucopyra-
noside (indicated by + signs) in the presence of 0.5 M NaCl, or 0.1 M NaCl+10 mM sodium cholate. 
hydrophobic surfaces, raising the possibility of protein aggre-
gation via hydrophobic interactions. 
Compatible with the presence of exposed hydrophobic sur-
faces, concanavalin A sepharose binding experiments and size 
exclusion chromatography suggested that cholesterol esterase 
undergoes partial aggregation in the absence of the glycosyl-
ated C-terminal domain. In the cell culture expression system 
the fully active truncated mutant is expressed as 58 kDa and 
63 kDa protein forms, as measured by SDS/PAGE (Fig. 2, 
left panel) [12]. The 63 kDa species arises from carbohydrate 
at an AMinked site (Asn-187) as shown by the generation of 
the 58 kDa form by A^-glycosidase F cleavage [13]. Purifica-
tion by concanavalin A sepharose effectively separates these 
two forms with specific elution of the bound 63 kDa N-linked 
glycosylated species by 0.2 M methyl-a-D-glucopyranoside 
(left panel). 
In the presence of 0.5 M NaCl, a small fraction of the 58 
kDa form was associated with the 63 kDa species (left panel). 
The possibility was considered that this association was an 
artifact, due either to alternative glycosylation, or a non-spe-
cific interaction of the 58 kDa form with the column matrix. 
However, an artifact was incompatible with the absence of 
non-specific binding under similar conditions in size exclusion 
chromatography, and with the loss of the 58 kDa form at a 
lower NaCl concentration (50 mM) (left panel). Interestingly, 
the association between the 58 kDa and 63 kDa recombinant 
forms was enhanced in the presence of 2 mM CHAPS. A 
possibility is that CHAPS binds to cholesterol esterase and 
enhances aggregation via an increase in hydrophobic surface 
area. 
Further supportive evidence for salt-dependent partial ag-
gregation was obtained by size exclusion chromatography 
(Fig. 3). Under conditions otherwise identical to Fig. 1, two 
additional higher molecular mass species appeared reproduci-
bly in the presence of 0.5 M NaCl, suggesting the existence of 
aggregated states. One of these peaks appeared near the void 
column volume while the other corresponded to an apparent 
molecular mass of approximately 126 kDa. 
Under these conditions, an aggregated state could be ener-
getically favourable, in which normally exposed hydrophobic 
surfaces are shielded from the aqueous solvent. Interestingly, 
a similar phenomenon is observed with the distantly related 
fungal lipase from Candida cylindracea [19] which exists in 
equilibrium with dimeric and monomeric forms [20]. Recent 
structural analysis has revealed a dimeric association of 
monomers in which the two active-site cavities face each oth-
er, shielding hydrophobic surfaces from the aqueous environ-
ment [21]. 
The partial aggregation of the truncated recombinant mu-
tant indicates a further role for the C-terminal glycosylated 
domain. This region has attracted much interest from several 
laboratories [12,13,22,23]. Although catalytically non-essen-
tial, they appear to be involved in soluble heparin interactions 
[23] and mediate substrate delivery [22]. Despite one report 
[24], they protect the protein molecule against proteolytic deg-
radation by pancreatic proteases [12]. In the present study, 
partial aggregation was not exhibited by the full length re-
combinant form. This comparative difference indicates that 
the glycosylated C-terminal domain counteracts a tendency 
for cholesterol esterase to self-aggregate. 
In conclusion, the present results refocus an aspect of bile 
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Fig. 3. Aggregrated forms of the truncated recombinant mutant. 
The truncated recombinant mutant (60 ug protein) was resolved on 
a Superose-12 column (Pharmacia) equilibrated with 10 mM sodium 
phosphate, pH 7.6, +0.5 M NaCl. Under these conditions, two 
higher molecular mass species appeared near the void column vol-
ume and at approximately 126 kDa. 
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salt activation by showing that bile salts do not induce dimer-
isation at both submicellar and micellar concentrations. Thus, 
protein dimerisation is not an obligatory component of the 
bile salt-activated pathway. An additional role for the glyco-
sylated C-terminal domain is also demonstrated in preventing 
non-specific intermolecular hydrophobic interactions. 
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